NIP
FOLD

Nicholas Investment Partners’s Amicus Therapeutics FOLD Stock Holding History

Nicholas Investment Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-142,419
Closed -$1.72M – 229
2018
Q3 		$1.72M Sell
142,419
-1,891
-1% -$26.4K 0.14% 194
2018
Q2 		$2.25M Buy
144,310
+17,912
+14% +$271K 0.16% 180
2018
Q1 		$1.9M Buy
126,398
+8,377
+7% +$127K 0.14% 193
2017
Q4 		$1.7M Sell
118,021
-16,367
-12% -$225K 0.11% 224
2017
Q3 		$2.03M Buy
+134,388
New +$1.78M 0.14% 211
2016
Q3 		– Sell
-317,716
Closed -$1.74M – 308
2016
Q2 		$1.74M Buy
+317,716
New +$2.22M 0.12% 265

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nicholas Investment Partners's FOLD Position: Q4 2018 in Review

Nicholas Investment Partners sold out of Amicus Therapeutics (FOLD) in Q4 2018, closing a stake of 142,419 shares — an estimated $1.72M sold.

Nicholas Investment Partners first reported a position in FOLD in Q2 2016 and held it in 6 quarters. The position peaked at $2.25M in Q2 2018. 195 funds tracked by Wall St. Rank hold FOLD as of Q4 2018.

  • Nicholas Investment Partners reported no remaining Amicus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Nicholas Investment Partners sold 142,419 Amicus Therapeutics shares in Q4 2018, an estimated $1.72M.
  • Nicholas Investment Partners first reported a position in Amicus Therapeutics in Q2 2016 and held it in 6 quarters.
  • Nicholas Investment Partners's Amicus Therapeutics position peaked at $2.25M in Q2 2018.
  • 195 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2018.

Based on Nicholas Investment Partners's 13F filing for Q4 2018, filed 14 Feb 2019.